Kurt A. Gustafson
Kurt A. Gustafson's purchase track record
Kurt A. Gustafson has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/28/2022 | OABI | $28K | +38.5% | +49.6% | +6.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
OmniAb (OABI) Shares Analyst/Investor Day Slideshow. OmniAb released a slideshow from its recent Analyst/Investor Day on Seeking Alpha. The presentation offered updates on the company's pipeline and strategic plans. The material provides investors with additional detail that may influence expectations, especially as the stock trades near its recent support level of $1.48 and below the average analyst target of $8.40.
Transaction History
| XNCR | ▲ Buy | Grant | 10,302 | $0 | 6/16/2026 | View on chart |
| XNCR | ▼ Sell | Open Market | 5,474 | $67K | 6/15/2026 | View on chart |
| OABI | ▲ Buy | Option Exercise | 13,542 | $0 | 4/7/2026 | View on chart |
| OABI | ▼ Sell | Open Market | 6,913 | $10K | 4/7/2026 | View on chart |
| OABI | ▲ Buy | Option Exercise | 18,750 | $0 | 2/18/2026 | View on chart |
| OABI | ▼ Sell | Open Market | 9,301 | $16K | 2/18/2026 | View on chart |
| OABI | ▼ Sell | Open Market | 6,828 | $12K | 2/17/2026 | View on chart |
| OABI | ▲ Buy | Option Exercise | 13,542 | $0 | 2/16/2026 | View on chart |
| OABI | ▼ Sell | Open Market | 23,922 | $47K | 12/8/2025 | View on chart |
| OABI | ▲ Buy | Option Exercise | 46,500 | $0 | 12/7/2025 | View on chart |
| XNCR | ▼ Sell | Open Market | 2,993 | $28K | 6/16/2025 | View on chart |
| XNCR | ▲ Buy | Grant | 13,686 | $0 | 6/12/2025 | View on chart |
| OABI | ▲ Buy | Option Exercise | 13,542 | $0 | 4/7/2025 | View on chart |
| OABI | ▼ Sell | Open Market | 7,206 | $14K | 4/7/2025 | View on chart |
| OABI | ▲ Buy | Option Exercise | 23,244 | $0 | 4/1/2025 | View on chart |
| OABI | ▼ Sell | Open Market | 11,963 | $28K | 4/1/2025 | View on chart |
| OABI | ▼ Sell | Open Market | 7,255 | $27K | 2/19/2025 | View on chart |
| OABI | ▲ Buy | Option Exercise | 13,541 | $0 | 2/16/2025 | View on chart |
| OABI | ▼ Sell | Open Market | 15,526 | $50K | 1/21/2025 | View on chart |
| OABI | ▲ Buy | Grant | 27,585 | $0 | 1/17/2025 | View on chart |
| OABI | ▼ Sell | Open Market | 23,871 | $99K | 12/9/2024 | View on chart |
| OABI | ▲ Buy | Option Exercise | 46,501 | — | 12/7/2024 | View on chart |
| XNCR | ▼ Sell | Open Market | 2,503 | $52K | 9/27/2024 | View on chart |
| XNCR | ▲ Buy | Grant | 5,986 | $0 | 6/13/2024 | View on chart |
| OABI | ▼ Sell | Open Market | 6,954 | $37K | 4/8/2024 | View on chart |
| OABI | ▲ Buy | Option Exercise | 13,541 | — | 4/7/2024 | View on chart |
| OABI | ▲ Buy | Option Exercise | 23,254 | — | 4/1/2024 | View on chart |
| OABI | ▼ Sell | Open Market | 11,849 | $65K | 4/1/2024 | View on chart |
| XNCR | ▲ Buy | Option Exercise | 15,000 | $161K | 3/6/2024 | View on chart |
| XNCR | ▼ Sell | Open Market | 14,000 | $324K | 3/6/2024 | View on chart |
| OABI | ▲ Buy | Option Exercise | 46,503 | — | 12/7/2023 | View on chart |
| OABI | ▼ Sell | Tax Withholding | 16,081 | $78K | 12/7/2023 | View on chart |
| XNCR | ▲ Buy | Grant | 5,007 | $0 | 6/20/2023 | View on chart |
| OABI | ▲ Buy | Grant | 40,625 | $0 | 4/7/2023 | View on chart |
| OABI | ▼ Sell | Tax Withholding | 8,042 | $30K | 4/1/2023 | View on chart |
| OABI | ▲ Buy | Grant | 139,504 | $0 | 1/3/2023 | View on chart |
| OABI | ▼ Sell | Tax Withholding | 6,733 | $23K | 12/1/2022 | View on chart |
| OABI | ▲ Buy | Open Market | 10,000 | $28K | 11/28/2022 | View on chart |
| OABI | ▲ Buy | Grant | 160,062 | — | 11/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
XNCR: Improved Funding for Obexelimab
Xencor announced that it has secured better funding for its experimental antibody Obexelimab, which could support further development of the therapy. The news comes as the stock is near its 18‑touch support level of $12 and still below the 52‑week low of $10.38. Analysts maintain a target of $31.42, indicating that the funding may help the company move toward that goal.
XNCR: Improved Funding for Obexelimab. Xencor announced that it has secured better funding for its experimental antibody Obexelimab, which could support further development of the therapy. The news comes as the stock is near its 18‑touch support level of $12 and still below the 52‑week low of $10.38. Analysts maintain a target of $31.42, indicating that the funding may help the company move toward that goal.